首页> 外国专利> Polymorphisms of the 5 region of the human 5-HT1A gene, associated proteins of the 5 region and a diagnostic test for major depression and related mental illnesses

Polymorphisms of the 5 region of the human 5-HT1A gene, associated proteins of the 5 region and a diagnostic test for major depression and related mental illnesses

机译:人5-HT1A基因5个区域的多态性,5个区域的相关蛋白以及重大抑郁症和相关精神疾病的诊断测试

摘要

Clinical response to antidepressant compounds correlates with a selective down-regulation of presynaptic 5-HT1A receptors in serotonergic raphe neurons. Thus regulation of the 5-HT1A receptor gene could play a crucial role in the treatment or etiology of major depression. The promoter and repressor activities of the human 5-HT1A receptor gene have been examined. The analysis of the 5-flanking regions of the 5-HT1A receptor gene has revealed a segment located between about 3438 and about 393 bp upstream from the initiator ATG that mediates cell-specific repression of the gene that is greater in cells that do not express the 5-HT1A receptor. The sequence of part of this region in patients with major depression was examined and a polymorphic C-G change located at 1019 bp (numbered earlier as 1017) was identified, which is associated with major depression. Thus, this sequence can be used as a genetic marker for major depression and related mental illnesses. Proteins that bind to the DNA at the 1019 locus have been identified. Such proteins that bind to this DNA region, for example the transcription factors NUDR/DEAF-1/suppressin and HES-5, are important targets for the development of therapeutic compounds for the treatment of major depression and related mental illness that involve the serotonin system. In addition the promoter region from about 393 to the initiator ATG displays glucocorticoid-mediated repression.
机译:对抗抑郁化合物的临床反应与血清素能神经元神经元中突触前5-HT1A受体的选择性下调有关。因此,调节5-HT1A受体基因可以在重度抑郁症的治疗或病因中起关键作用。已经检查了人5-HT1A受体基因的启动子和阻遏物活性。对5-HT1A受体基因的5个侧翼区域的分析表明,在起始剂ATG上游约3438到393 bp之间存在一个片段,该片段介导了该基因的细胞特异性阻遏,在不表达的细胞中更大5-HT1A受体。检查了重度抑郁症患者该区域的部分序列,发现了一个多态性C-G改变,位于1019 bp(之前编号为1017),与重度抑郁症有关。因此,该序列可用作严重抑郁症和相关精神疾病的遗传标记。已经鉴定出在1019位点与DNA结合的蛋白质。这类与该DNA区域结合的蛋白质,例如转录因子NUDR / DEAF-1 / suppressin和HES-5,是开发用于治疗涉及5-羟色胺系统的重大抑郁症和相关精神疾病的治疗化合物的重要目标。另外,从大约393到启动子ATG的启动子区域显示糖皮质激素介导的阻抑。

著录项

  • 公开/公告号US2004171083A1

    专利类型

  • 公开/公告日2004-09-02

    原文格式PDF

  • 申请/专利权人 ALBERT PAUL;LEMONDE SYLVIE;

    申请/专利号US20030635855

  • 发明设计人 PAUL ALBERT;SYLVIE LEMONDE;

    申请日2003-08-05

  • 分类号C12Q1/68;G01N33/53;G01N33/567;

  • 国家 US

  • 入库时间 2022-08-21 23:21:32

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号